Key regions: Germany, United States, India, Japan, United Kingdom
The Anti-Rheumatic Drugs market in North Macedonia has been showing a steady growth rate in recent years.
Customer preferences: Patients suffering from rheumatoid arthritis and other rheumatic disorders generally prefer to opt for biologic drugs as these drugs have fewer side effects and are more effective in treating the symptoms. However, the high cost of biologic drugs is a major concern for patients in North Macedonia, and many of them opt for cheaper alternatives such as non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids.
Trends in the market: The demand for anti-rheumatic drugs in North Macedonia has been increasing due to the rising prevalence of rheumatoid arthritis and other rheumatic disorders. The market has been witnessing a shift towards biologic drugs, which offer better efficacy and safety compared to traditional disease-modifying anti-rheumatic drugs (DMARDs). However, the high cost of biologic drugs is a major challenge for the growth of the market, and many patients opt for cheaper alternatives such as NSAIDs and corticosteroids. The government has been taking steps to increase the affordability of biologic drugs by introducing reimbursement policies and price controls.
Local special circumstances: North Macedonia has a relatively small population, and the market for anti-rheumatic drugs is highly concentrated. The market is dominated by multinational pharmaceutical companies, and there are only a few local players. The lack of local manufacturing facilities for biologic drugs is a major challenge for the growth of the market, as these drugs need to be imported, which increases their cost.
Underlying macroeconomic factors: The healthcare sector in North Macedonia has been undergoing significant reforms in recent years, with the government taking steps to improve the quality and accessibility of healthcare services. The increasing focus on healthcare is expected to drive the growth of the anti-rheumatic drugs market in the country. However, the low per capita income and high unemployment rate in North Macedonia are major challenges for the growth of the market, as many patients may not be able to afford expensive biologic drugs. The government has been taking steps to address these issues by introducing reimbursement policies and price controls.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
